First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

Abstract Cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) represents a first-line therapeutic standard for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients. Despite this established approach, cetuximab β (CMAB009), as a modified antibody of cetuximab, prospectively se...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuankai Shi, Yi Ba, Junye Wang, Jianping Xiong, Kangsheng Gu, Yigui Chen, Zhendong Zheng, Zishu Wang, Weijian Guo, Ying Cheng, Xianli Yin, Yunpeng Liu, Yuxian Bai, Enxiao Li, Qi Li, Liangjun Zhu, Wei Li, Da Jiang, Jingdong He, Jiansi Chen, Jianguo Sun, Sheng Hou
Format: Article
Language:English
Published: Nature Publishing Group 2025-05-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02229-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-025-02229-4

Similar Items